PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy

September 10, 2009

OXFORD, England, September 10 /PRNewswire/ -- PharmaVentures announced today the appointment of Nikki Watkins as Head of the Product & Portfolio Strategy Practice of Corporate Advisory, leading a team of Senior Advisors and Analysts.

Fintan Walton, PhD, PharmaVentures' Chief Executive Officer says, "We are delighted to welcome Nikki to PharmaVentures. Our Corporate Advisory business is currently undergoing exciting developments, and extensive knowledge of portfolio assessment and strategy from GSK and PricewaterhouseCoopers will be a key contributor to our growth plans."

Tibor Papp, PhD, Head of Corporate Advisory Ltd, says, "Nikki brings substantial industry and advisory experience into PharmaVentures. She will take on a leadership role, further developing our practice in strategic analysis of products, companies and markets. With Nikki's experience, PharmaVentures further strengthens its leading position as shapers of the industry."

Nikki has an honours degree in Pharmacology from Cambridge University. Most recently, she was the Director of Portfolio Consolidation & Analysis, Global Product Strategy, R&D at GlaxoSmithKline (GSK).

Nikki brings additional industry experience to PharmaVentures from various previous roles in GSK R&D, commercial analysis, portfolio management and global internal audit. Prior to this, she qualified as a Chartered Accountant at PricewaterhouseCoopers.

Notes to Editors:

About PharmaVentures

A leading results driven organisation, PharmaVentures (http://www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making and business intelligence. The Company provides tailored corporate advisory services to the Life Science industry, with additional deal making support provided through the PharmaDeals(R) range of intelligence products that include analysis tools and reports. An innovative business, PharmaVentures additionally provides industry insight through the world's first dedicated online pharmaceutical television channel http://www.pharmatelevision.com.

Now in its 17th year, PharmaVentures is based in Oxford, UK, employs over 50 people mostly educated to PhD or above, and has increased its turnover five fold with 80% of revenues from outside the UK. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporate pharmaceutical companies.

    
    PharmaTelevision(R) and PharmaDeals(R) are registered Trade Marks of
    PharmaVentures Ltd.
    
    For further information about PharmaVentures, please contact:

    Lisa Holloway, Marketing
    +44(0)1865-784-177
    lisa.holloway@pharmaventures.com